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Adverse reactionsAbstract Background: Pulmonary tuberculosis is a major cause of morbidity and mortality
worldwide, resulting in the greatest number of deaths due to any one single infectious agent.
Drug resistance threatens global tuberculosis control efforts.
Objective: The aim of this study was to assess adverse reactions of second-line TB drugs in
patients treated for MDR-TB at Abbassia Chest Hospital from 1st of January 2009 to 1st of
January 2012.
Subjects and methods: This study included 107 patients admitted at Abbassia Chest Hospital;
during the period from January 2009 to January 2012. The patients were resistant to at least
Rifampicin and INH. All patients’ ﬁles were analyzed and the following data were discussed: metic-
ulous history taking, complete clinical examination, drug susceptibility testing, and initial labora-
tory investigations, adverse reactions were determined by clinical criteria and/or laboratory data,
severity code, management of side effects and fate of treatment.
Results: 72.9% of the patients were males and 27.1% were females. The mean of age was
37.1 years. The special habits detected among the studied cases were tobacco smoking, drug addic-
tion and alcohol intake. According to type of resistance, acquired resistance was 95.3% and pri-
mary resistance was 4.7%. The most common co-morbidities associated with MDR-TB in the
studied cases were diabetes (29.9%) and chronic obstructive lung disease (11.2%). Side effects of
drugs were; 57% GIT manifestations, 53.3% peripheral neuritis, hypokalemia 26.2%, irritable
bowel syndrome 22.4%, ototoxicity 17.8%, skin reaction 10.3%, hypothyroidism 10.3%, hepato-
toxicity 9.3%, hypoalbuminemia 5.6%, depression 3.7%, arthritis 0.9%, gynecomastia 2.8%,
940 M.A. Tag El Din et al.hyponatremia 5.6%, hypomagnesaemia 1.9%, dizziness 0.9%, nephrotoxicity 3.7%. Most of the
drugs’ side effects started to appear within the ﬁrst 3 months of treatment. The frequency of
nephrotoxicity, hepatotoxicity and hypoalbuminemia were signiﬁcantly higher in diabetic than in
non-diabetic cases. Elevations of liver enzymes began from the 3rd month after treatment and these
elevations became statistically signiﬁcant beginning from the 6th month. Also, elevations of crea-
tinine levels began from the 3rd month after treatment and became statistically signiﬁcant beginning
from the 6th month, while there were no signiﬁcant changes in potassium levels among the studied
cases all through the follow up period. It was noticed that highly signiﬁcant gain of body weight
started from the 3rd month after treatment. 92.5% of the studied cases were cured, 6.5% died
and 0.9% was defaulter. The predictors of patients’ outcome were sputum conversion, number
of previous TB treatment and associated co-morbidities.
Conclusions: There is a relation between both tobacco smoking and drug addiction, and MDR
TB. The most common type of resistance is acquired resistance because of lack of adherence to
treatment or inappropriate treatment. The most common co-morbidities associated with MDR
TB are diabetes and chronic obstructive lung diseases. The most important predictors of patients’
outcome are sputum conversion, number of previous TB treatment and presence of co-morbidities.
ª 2015 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Tuberculosis (TB) is an infectious bacterial disease caused by
Mycobacterium tuberculosis, which most commonly affects
the lungs. It is transmitted from person to person via droplets
from the throat and lungs of people with the active respiratory
disease [1].
Approximately 9.4 million new cases and 1.7 million deaths
were encountered per year worldwide [2].
Morbidity and mortality are especially high in speciﬁc pop-
ulations such as those with underlying immunosuppression or
very young children [3].
Tuberculosis remains a public health problem in Egypt.
Although Egypt is in the era of epidemiological transition
from communicable to non-communicable diseases like many
other countries, TB, still, must be addressed and handled as
a health problem affecting large sectors in the society, espe-
cially the poor and the vulnerable [4].
Early diagnosis and immediate initiation of treatment are
essential for an effective TB control program. Delay in diagno-
sis is signiﬁcant to both disease prognosis at the individual
level and transmission within the community. Most transmis-
sions occur between the onset of cough and initiation of treat-
ment. The diagnosis of pulmonary TB depends on clinical
suspicion, response to treatment, chest radiographs, staining
for acid fast bacilli (AFB), culture for TB, and, nucleic acid
ampliﬁcation (NAA) assays [5].
The most effective anti-TB drugs are Isoniazid (INH) and
Rifampicin (RIF). Resistant Mycobacteria to at least one of
these drugs are the cause of Multidrug-resistant tuberculosis
(MDR-TB). This type of resistance is highly problematic due
to limited sources of drugs as well as the high toxicity, low efﬁ-
cacy and high cost of second-line tuberculosis drugs [6].
Multidrug-resistant TB (MDR-TB) is caused by bacteria
that are resistant to at least Isoniazid and Rifampicin, the most
effective anti-TB drugs. MDR-TB results from either primary
infection with resistant bacteria or may develop in the course
of a patient’s treatment [7].
In 2008, an estimated 390,000–510,000 case of MDR-TB
emerged globally. Among TB cases, 3.6% are estimated tohave MDR-TB. Twenty-two of 48 African countries reported
ﬁrst-line TB drug resistance, the estimated number of MDR-
TB cases (primary and acquired) in 2008 was 69,000 (53,000–
110,000). Although the rate of drug resistance is continuously
increasing, only around 7% of estimated cases are detected.
The control of drug resistant disease is difﬁcult especially in
high burden countries due to poor laboratory services and
the slow nature of conventional drug susceptibility testing [8].
In Egypt, a nationwide drug resistance survey was carried
out in 2002, in which a total number of 849 patients enrolled,
632 new and 217 old patients [4].
There are several ways that drug resistance to TB and drug
resistance in general, can be prevented:
 Rapid diagnosis and treatment of TB.
 Completion of treatment.
 Patients with HIV/AIDS should be identiﬁed and diag-
nosed as soon as possible.
 Identify contacts who could have contracted TB: i.e. family
members, people in close contact, etc.
 Research: Much research and funding is needed in the diag-
nosis, prevention and treatment of TB and MDR TB [9,10].
The emergence of multidrug resistant TB (MDR-TB), i.e.
which is resistant to at least Isoniazid (INH) and Rifampicin
(RIF), is of great concern, because it requires the use of sec-
ond-line drugs that are difﬁcult to procure and are much more
toxic and expensive than FLDs [11].
Laboratory monitoring is required for patients receiving a
regimen with second-line anti-TB drugs. Adverse effects can
be occult (not obviously noted by taking the history of the
patient or by physical examination). Note the following impor-
tant aspects of laboratory monitoring for adverse effects:
 Renal toxicity monitoring
 Electrolyte monitoring
 Monitoring for hypothyroidism
 Monitoring liver toxicity
 Pregnancy testing
 Audiometry [12].
Adverse reactions among MDR-TB patients 941Subjects and methods
This was a retrospective study, that included (107) MDR
patients admitted at Abbassia Chest Hospital between 1st
January 2009 and 1st January 2012.
 Inclusion criteria:
X All patients included in this study were diagnosed in the
same year as MDR.
X They were resistant to at least Rifampicin and INH.
 Exclusion criteria:
X MDR patients readmitted after discharge.
All patients’ ﬁles were analyzed and the following data were
discussed:
 Meticulous history taking with special attention to:
X Whether primary or secondary resistance.
X History of second-line TB drugs.
X Patient’s compliance and follow up of treatment.
X History of HIV infection.
 Complete clinical examination.
 Drug Susceptibility testing:
Susceptibility was performed by conventional Drug
Incorporation Method, using 4 anti-tuberculous agents:
Isoniazid, Streptomycin, Rifampicin and Ethambutol.
 The initial laboratory investigations:
– Sputum examination:X Direct smear examination using Ziehl–Nielsen stain.
– Drug susceptibility tests for ﬁrst-line anti-TB drugs.
– Complete blood count (CBC).
– ESR.
– Fasting and two hours post prandial blood sugar.
– Serum sodium and potassium on admission then on
demand.
– Liver functions:
X Total serum bilirubin.
X SGPT and SGOT.
X Serum albumin, total serum protein and A/G ratio.
– Renal functions:
X Serum creatinine
– HIV testing.
 The patient received the following regimen, if proved to be
MDR-TB:
 Regimen (1): Kanamycin, Ethionamide, Cycloserine, PAS,
Oﬂoxacin.
 Regimen (2): Amikacin, Ethionamide, Cycloserine, PAS,
Oﬂoxacin.
 Regimen (3): Capreomycin, Ethionamide, Cycloserine,
PAS, Oﬂoxacin.
 Regimen (4): Streptomycin, Ethionamide, Cycloserine,
PAS, Oﬂoxacin. Ethambutol + Ethionamide, Cycloserine, PAS,
Oﬂoxacin + one of the injectable drugs.
 Adverse reactions were determined by clinical criteria
and/or laboratory data such as:
X Sputum smears and culture; monthly until conversion,
then smears monthly and culture quarterly.
X Chest X-ray every 6 months.
X Serum creatinine, monthly while receiving injectable
drugs.
X Serum potassium and sodium; monthly while receiving
injectable drugs.
X Liver enzymes; periodic monitoring (every 1–3 months).
X Thyroid stimulating hormone (TSH) every 6 months if
receiving Ethionamide or Para amino-salicylic acid and
monthly for signs and symptoms of hypothyroidism.
X Audiometry, visual acuity and color vision evaluation,
psychiatric disorders assessment, hematological chan-
ges and allergic reactions when indicated.
 Side effects of 2nd line treatment:
X Ototoxicity.
X Psychiatric disorders.
X Gastrointestinal effects.
X Arthralgia, arthritis.
X Central nervous system (CNS): seizures.
X Hepatotoxicity.
X Dermatological.
X Leucopenia.
X Peripheral neuropathy.
X Nephrotoxicity.
X Hypothyroidism.
 Severity code:
X Asymptomatic.
X Does not affect daily activities.
X Limits daily activities.
X Life threatening hospitalization.
 Management of side effects:
X Reduced Dosage of Suspected Drug(s).
X Removal of Drug(s) from the Regimen.
X Speciﬁc treatment for every adverse reaction.
 Fate of treatment:
X Cured.
X Defaulter.
X Treatment failure and begin re-treatment course.
X Died.Statistical methods
X The collected data were coded, tabulated, and statistically
analyzed using SPSS Program (Statistical Package for
Social Sciences) software version 18.0.
X Descriptive statistics were done for quantitative parametric
data as minimum and maximum of the range as well as
mean ± SD (standard deviation) for numerical parametric
and median and 1st and 3rd inter-quartile range for numer-
ical non parametric, while they were done for qualitative
data as number and percentage.
Table 3 Co-morbidities among the studied cases.
Co-morbidities No. %
DM 32 29.9
Chronic liver disease 4 3.7
Chronic renal disease 1 0.9
Ischemic heart disease 2 1.9
Chronic pulmonary disease 12 11.2
HIV 1 0.9
No co-morbidities 55 51.4
N= 107.
Table 4 Types of resistance among the studied cases.
N %
Resistance
 1ry
 2ry
5
102
4.7
95.3
N= 107.
Table 5 Anti-tuberculous drugs used among the studied
cases.
Drugs N %
Ethionamide 107 100.0
942 M.A. Tag El Din et al.X Inferential analyses were done for quantitative variables
using paired t-test in cases of two dependent groups with
parametric data and Wilcoxon signed rank test in cases of
two dependent groups with non-parametric data. In quali-
tative data, inferential analyses for independent variables
were done using Chi square test for differences between
proportions.
X The level of signiﬁcance was taken at P value <0.050 is sig-
niﬁcant, otherwise is non-signiﬁcant. The P-value is a statis-
tical measure for the probability that the results observed in
a study could have occurred by chance.
Results
Table 1 shows that follow up data were available for 107
patients, while only 26 patients completed one year of follow
up data.
The mean age of the studied cases was 37.1 years, males
represented 72.9% of the cases and females represented
27.1%. Table 2 also shows the frequency of associated special
habits among the studied cases (smoking 27.1%, addiction
5.6%, alcohol 3.7%).
Table 3 shows that 49.6% of the patients had co-morbidi-
ties {29.9% of them were diabetic, 3.7% had chronic liver dis-
ease, 11.2% had COPD and only one patient was HIV
positive}.
Table 4 shows that 102 patients were 2ry resistant and ﬁve
patients were 1ry resistant to anti TB drugs.
Table 5 shows the 2nd line drugs prescribed to the patients,
in which all of them shared 4 drugs (Ethionamide –
Cycloserine – PAS – Oﬂoxacin), but they differed as regards
the injectable drugs (Kanamycin 53 – Amikacin 33 –
Capreomycin 14 – Streptomycin 7 – Ethambutol 22).Table 1 Available follow up data of the studied cases.
Month No.
1st month 107
3rd month 104
6th month 89
9th month 49
12th month 26
Table 2 Demographic and special habits of the studied cases.
Mean ± SD Range
Age (years) 37.1 ± 11.9 15.0–67.0
N %
Sex
Female 29 27.1
Male 78 72.9
Smoking 29 27.1
Addiction 6 5.6
Alcohol 4 3.7
N= 107.Table 6 shows the different anti TB regimens prescribed to
the studied cases.
Table 7 shows that the majority of cases cured after treat-
ment (99 patients), one patient was defaulter and only seven
patients died.
Table 8 and Fig. 1 show that the elevations of SGPT began
from the 3rd month after starting treatment and theseCycloserine 107 100.0
PAS 107 100.0
Oﬂoxacin 107 100.0
Kanamycin 53 49.5
Amikacin 33 30.8
Ethambutol 22 20.6
Capreomycin 14 13.1
Streptomycin 7 6.5
N= 107.
Table 6 Anti-tuberculous Regimens used among the studied
cases.
N %
Regimen (1) Kanamycin, Ethionamide, Cycloserine,
PAS, Oﬂoxacin
53 49.5
Regimen (2) Amikacin, Ethionamide, Cycloserine, PAS,
Oﬂoxacin
33 30.8
Regimen (3) Capreomycin, Ethionamide, Cycloserine,
PAS, Oﬂoxacin
14 13.1
Regimen (4) Streptomycin, Ethionamide, Cycloserine,
PAS, Oﬂoxacin
7 6.5
Ethambutol + Ethionamide, Cycloserine, PAS,
Oﬂoxacin + one of injectable drugs
22 20.6
N= 107.
Table 9 Creatinine (mg/dL) among the studied cases.
Month No. Mean ± SD Range #P
1st month 107 0.88 ± 0.20 0.60–2.10
3rd month 104 0.91 ± 0.33 0.60–3.30 0.434
6th month 89 0.95 ± 0.34 0.60–2.80 0.047*
9th month 49 0.96 ± 0.27 0.50–1.90 0.006*
12th month 26 0.95 ± 0.28 0.60–2.00 0.049*
# Paired t-test, difference from each month to 1st month.
* Signiﬁcant.
Adverse reactions among MDR-TB patients 943elevations became statistically signiﬁcant beginning from the
6th month.
Table 9 and Fig. 2 show that elevations of creatinine level
began from the 3rd month after starting treatment and became
statistically signiﬁcant beginning from the 6th month.
Table 10 and Fig. 3 show that there were no signiﬁcant
changes in potassium levels among the studied cases all
through the follow up period.
Table 11 and Fig. 4 show that highly signiﬁcant gain of
body weight started from the 3rd month after the beginning
of the treatment.
Table 12 and Fig. 5 show that GIT manifestations was the
most frequent side effect, followed by PN, Hypokalemia, IBS,
ototoxicity, Hypothyroidism, Skin manifestations,
Hepatotoxicity and nephrotoxicity.Table 7 Outcome of the studied cases.
No. %
Negative sputum 99 92.5
Treatment default 1 0.9
Died 7 6.5
Table 8 SGPT (IU/L) among the studied cases.
Month No. Median (IQR) Range #P
1st month 107 15.0 (12.0–22.0) 0.7–164.0
3rd month 104 16.0 (14.0–22.0) 0.6–181.0 0.252
6th month 89 18.0 (15.0–23.0) 0.7–91.0 0.049*
9th month 49 18.0 (15.0–24.0) 0.9–226.0 0.050*
12th month 26 21.5 (14.0–30.3) 12.0–330.0 0.019*
IQR: Interquartile range.
# Wilcoxon signed rank test, difference from each month to 1st
month.
* Signiﬁcant.
Figure 1 SGPT among the studied cases.
Figure 2 Creatinine among the studied cases.
Table 10 Potassium (mmol/L) among the studied cases.
Month No. Mean ± SD Range #P
1st month 107 4.05 ± 0.40 3.10–5.50
3rd month 104 4.04 ± 0.54 2.70–6.10 0.958
6th month 89 4.10 ± 0.48 2.40–5.20 0.450
9th month 49 4.06 ± 0.55 2.60–5.80 0.938
12th month 26 4.08 ± 0.45 3.40–5.00 0.223
# Paired t-test, difference from each month to 1st month.Table 13 shows the severity of adverse reactions; (1)
Asymptomatic, (2) Does not affect daily activities, (3) Limits
daily activities.
Table 14 shows that most of the drugs’ side effects started
to appear within the ﬁrst 3 months after starting treatment.
Table 15 and Fig. 6 show that there was no signiﬁcant rela-
tion between Kanamycin and ototoxicity.
Table 16 and Fig. 7 show that there was no signiﬁcant rela-
tion between Amikacin and Streptomycin, and hypokalemia.
Table 17 and Fig. 8 show that there was no signiﬁcant rela-
tion between Streptomycin and IBS.
Table 18 and Fig. 9 show that there was no signiﬁcant rela-
tion between Amikacin and Streptomycin, and hepatotoxicity.
Table 19 and Fig. 10 show that there was signiﬁcant rela-
tion between Kanamycin and hypothyroidism.
Figure 3 Potassium among the studied cases.
Table 11 Weight gain (kg) among the studied cases.
Month No. Mean ± SD Range #P
1st month 107 59.9 ± 13.0 37.0–110.0
3rd month 104 61.2 ± 13.0 35.0–111.0 <0.001*
6th month 89 63.4 ± 13.1 38.0–112.0 <0.001*
9th month 49 65.7 ± 14.3 38.0–114.0 <0.001*
12th month 26 67.2 ± 15.2 40.0–107.0 <0.001*
# Paired t-test, difference from each month to 1st month.
* Signiﬁcant.
. 
Figure 4 Weight gain among the studied cases.
Table 12 Drugs’ side effects among the studied cases.
Side eﬀects No. %
Ototoxicity 19 17.8
Nephrotoxicity 4 3.7
Dizziness 1 0.9
Hypokalemia 28 26.2
Hypomagnesaemia 2 1.9
Hyponatremia 1 0.9
IBS 24 22.4
Hepatotoxicity 10 9.3
Gynecomastia 3 2.8
Hypothyroidism 11 10.3
Arthritis 1 0.9
GIT manifestations 59 57
PN 57 53.3
Hypoalbuminemia 6 5.6
Skin 11 10.3
Depression 4 3.7
N= 107.
Figure 5 Drugs’ side effects among the studied cases.
944 M.A. Tag El Din et al.Table 20 and Fig. 11 show that there was no signiﬁcant
relation between Kanamycin and GIT manifestations.
Table 21 and Fig. 12 show that there was no signiﬁcant
relation between Kanamycin and PN.
Table 22 and Figs. 13 and 14 show that: PN was signiﬁ-
cantly highest in Kanamycin regimen and least in
Capreomycin regimen. IBS was signiﬁcantly highest in
Streptomycin regimen and least in Capreomycin regimen.Table 23 and Fig. 15 show that the frequency of
Nephrotoxicity, Hepatotoxicity and Hypoalbuminemia was
signiﬁcantly higher in diabetic than in non-diabetic cases.
Discussion
Multi drug resistant tuberculosis (MDR-TB) is a growing haz-
ard to human health worldwide. MDR-TB is suspected if spu-
tum is persistently positive for acid fast bacilli with clinical and
radiological deterioration after multiple courses of irregular/
regular treatment. MDR tuberculosis is deﬁned as disease
due to M tuberculosis that is resistant to Isoniazid (H) and
Rifampicin (R), with or without resistance to other drugs3.
Primary drug resistance is deﬁned as drug resistance in a
patient who has not received any anti-tubercular treatment
in the past, while acquired drug resistance is deﬁned as resis-
tance that develops in a patient who has received prior
chemotherapy [13].
Table 13 Side effect severity among the studied cases.
Side eﬀects Severity No. %
Ototoxicity 1 8 42.1
2 11 57.9
Nephrotoxicity 1 1 25.0
2 3 75.0
Dizziness 2 1 100.0
Hypokalemia 1 3 10.7
2 24 85.7
3 1 3.6
Hypomagnesaemia 2 2 100.0
Hyponatremia 2 1 100.0
IBS 1 3 12.5
2 21 87.5
Hepatotoxicity 2 10 100.0
Gynecomastia 1 2 50.0
2 2 50.0
Hypothyroidism 1 5 45.5
2 6 54.5
Arthritis 2 1 100.0
GERD 1 15 25.4
2 43 72.9
3 1 1.7
PN 1 11 19.3
2 46 80.7
Hypoalbuminemia 1 3 50.0
2 3 50.0
Skin 1 3 27.3
2 8 72.7
Depression 1 3 75.0
2 1 25.0
Table 14 Side effect timings (month) among the studied cases.
Side eﬀects Total Median (IQR) Range
Ototoxicity 19 6.0 (5.0–7.0) 2.0–10.0
Nephrotoxicity 4 1.0 (1.0–1.0) 1.0–1.0
Dizziness 1 3.0
Hypokalemia 28 3.0 (2.0–4.0) 1.0–8.0
Hypomagnesaemia 2 1.0–6.0
Hyponatremia 1 2.0
IBS 24 4.0 (2.3–6.0) 1.0–10.0
Hepatotoxicity 10 5.0 (2.8–6.3) 1.0–8.0
Gynecomastia 4 6.0 (3.8–9.8) 3.0–11.0
Hypothyroidism 11 6.0 (3.0–7.0) 1.0–7.0
Arthritis 1 7.0
GERD 59 3.0 (2.0–4.0) 1.0–9.0
PN 57 3.0 (2.0–4.5) 1.0–12.0
Hypoalbuminemia 6 3.0 (2.5–3.5) 1.0–5.0
Skin 11 6.0 (4.0–7.0) 3.0–12.0
Depression 4 5.0 (1.0–10.5) 1.0–11.0
Table 15 Comparison between cases with and without oto-
toxicity as regards the prescribed anti-tuberculous drugs.
Anti-tuberculous
drugs
Present
(N= 19)
Absent
(N= 88)
#P
Kanamycin 13 (68.4%) 40 (45.5%) 0.069
Amikacin 4 (21.1%) 29 (33.0%) 0.308
Ethambutol 0 (0.0%) 22 (25.0%) 0.014*
Capreomycin 1 (5.3%) 13 (14.8%) 0.265
Streptomycin 1 (5.3%) 6 (6.8%) 0.804
# Chi square test.
* Signiﬁcant.
Figure 6 Comparison between cases with and without ototox-
icity as regards the prescribed anti-tuberculous drugs.
Table 16 Comparison between cases with and without
hypokalemia as regards the prescribed anti-tuberculous drugs.
Anti-tuberculous
drugs
Present
(N= 28)
Absent
(N= 79)
#P
Kanamycin 12 (42.9%) 41 (51.9%) 0.411
Amikacin 9 (32.1%) 24 (30.4%) 0.862
Ethambutol 4 (14.3%) 18 (22.8%) 0.339
Capreomycin 2 (7.1%) 12 (15.2%) 0.278
Streptomycin 2 (7.1%) 5 (6.3%) 0.881
# Chi square test.
Figure 7 Comparison between cases with and without hypoka-
lemia as regards the prescribed anti-tuberculous drugs.
Adverse reactions among MDR-TB patients 945Second line drugs are frequently associated with very high
rates of unacceptable adverse drug reactions, needing frequent
interruption and change of regimen. Some authors reported
that 41% of the patients experienced some side effects and only
21.1% of the patients required stoppage or change of drug in
their study of 39 patients of MDR-TB [14].
Close monitoring of the patient is necessary to ensure that
the adverse effects of second line drugs are recognized quickly.
The ability to monitor patients for adverse effects daily is oneof the major advantages of Directly Observed Treatment as in
category IV treatment running as a pilot project in some states
of India. The majority of adverse effects are easy to recognize.
Commonly, patients will volunteer that they are experiencing
adverse effects. However, it is important to have a systematic
Table 17 Comparison between cases with and without IBS as
regards the prescribed anti-tuberculous drugs.
Anti-tuberculous
drugs
Present
(N= 24)
Absent
(N= 83)
#P
Kanamycin 12 (50.0%) 41 (49.4%) 0.959
Amikacin 5 (20.8%) 28 (33.7%) 0.228
Ethambutol 3 (12.5%) 19 (22.9%) 0.267
Capreomycin 1 (4.2%) 13 (15.7%) 0.141
Streptomycin 3 (12.5%) 4 (4.8%) 0.180
# Chi square test.
Figure 8 Comparison between cases with and without IBS as
regards the prescribed anti-tuberculous drugs.
Table 18 Comparison between cases with and without hep-
atotoxicity as regards the prescribed antituberculous drugs.
Anti-tuberculous
drugs
Present
(N= 10)
Absent
(N= 97)
#P
Kanamycin 2 (20.0%) 51 (52.6%) 0.054
Amikacin 5 (50.0%) 28 (28.9%) 0.168
Ethambutol 1 (10.0%) 21 (21.6%) 0.385
Capreomycin 1 (10.0%) 13 (13.4%) 0.761
Streptomycin 1 (10.0%) 6 (6.2%) 0.642
# Chi square test.
Figure 9 Comparison between cases with and without hepato-
toxicity as regards the prescribed antituberculous drugs.
Table 19 Comparison between cases with and without
hypothyroidism as regards the prescribed antituberculous
drugs.
Anti-tuberculous
drugs
Present
(N= 11)
Absent
(N= 96)
#P
Kanamycin 9 (81.8%) 44 (45.8%) 0.024*
Amikacin 1 (9.1%) 32 (33.3%) 0.099
Ethambutol 1 (9.1%) 21 (21.9%) 0.320
Capreomycin 0 (0.0%) 14 (14.6%) 0.174
Streptomycin 0 (0.0%) 2 (2.1%) 0.629
# Chi square test.
* Signiﬁcant.
Figure 10 Comparison between cases with and without hypothy-
roidism as regards the prescribed antituberculous drugs.
Table 20 Comparison between cases with and without GIT
manifestations as regards the prescribed anti-tuberculous
drugs.
Anti-tuberculous
drugs
Present
(N= 61)
Absent
(N= 46)
#P
Kanamycin 20 (32.8%) 13 (28.3%) 0.616
Amikacin 22 (36.1%) 17 (37.0%) 0.924
Ethambutol 7 (11.5%) 6 (13.0%) 0.922
Capreomycin 7 (11.5%) 6 (13.0%) 0.922
Streptomycin 5 (8.2%) 4 (8.7%) 0.927
# Chi square test.
Figure 11 Comparison between cases with and without GIT
manifestations as regards the prescribed anti-tuberculous drugs.
946 M.A. Tag El Din et al.method of patient interviewing since some patients may be ret-
icent about reporting even severe adverse effects. Other
patients may be distracted by one adverse effect and forget
to tell the physician about others. The physician should betrained to screen patients regularly for symptoms of common
adverse effects: rashes, gastrointestinal symptoms (nausea,
vomiting, diarrhea), psychiatric symptoms (psychosis, anxiety,
Table 21 Comparison between cases with and without PN as
regards the prescribed anti-tuberculous drugs.
Anti-tuberculous
drugs
Present
(N= 57)
Absent
(N= 50)
#P
Kanamycin 32 (56.1%) 21 (42.0%) 0.144
Amikacin 13 (22.8%) 20 (40.0%) 0.055
Ethambutol 9 (15.8%) 13 (26.0%) 0.192
Capreomycin 1 (12.3%) 13 (14.0%) 0.792
Streptomycin 2 (3.5%) 5 (10.0%) 0.175
# Chi square test.
Figure 12 Comparison between cases with and without PN as
regards the prescribed anti-tuberculous drugs.
Figure 13 Comparison between Anti-TB regimens regarding
PN.
Figure 14 Comparison between Anti-TB regimens regarding
IBS.
Adverse reactions among MDR-TB patients 947depression, suicidal ideation), jaundice, ototoxicity and periph-
eral neuropathy [15].
Prompt evaluation, diagnosis and treatment of adverse
effects are extremely important, even if the adverse effect is
not particularly dangerous. If the adverse effect is mild and
not dangerous like peripheral neuropathy in our patient, con-
tinuing the treatment regimen, with the help of ancillary drugs
if needed, is often the best option [16].
The patient receives the following regimen, if proved to be
MDR-TB:Table 22 Comparison between Anti-TB regimens regarding compli
Complication Kanamycin
(N= 53)
Amikacin
(N= 33)
Capreo
(N= 1
Ototoxicity 13 (24.5%) 4 (12.1%) 1 (7.1%
Renal impairment 3 (5.7%) 1 (3.0%) 0 (0.0%
Dizziness 0 (0.0%) 1 (3.0%) 0 (0.0%
Hypomagnesaemia 0 (0.0%) 1 (3.0%) 1 (7.1%
Hyponatremia 0 (0.0%) 0 (0.0%) 1 (7.1%
Gynecomastia 1 (1.9%) 1 (3.0%) 0 (0.0%
Arthritis 1 (1.9%) 0 (0.0%) 0 (0.0%
Hypoalbuminemia 4 (7.5%) 2 (6.1%) 0 (0.0%
Skin disorders 5 (9.4%) 5 (15.2%) 0 (0.0%
Depression 3 (5.7%) 1 (3.0%) 0 (0.0%
GERD 35 (66.0%) 15 (45.5%) 5 (35.7
PN 32 (60.4%) 13 (39.4%) 1 (7.1%
Hypokalemia 12 (22.6%) 9 (27.3%) 2 (14.3
IBS 12 (22.6%) 5 (15.2%) 1 (7.1%
Hepatotoxicity 2 (3.8%) 5 (15.2%) 1 (7.1%
Hypothyroidism 9 (17.0%) 1 (3.0%) 0 (0.0%
^ Fisher Exact test.
* Signiﬁcant. Kanamycin daily for three months then every other day,
 +Levoﬂoxacin,
 +Ethionamide,
 +Cycloserine or +PAS.cations.
mycin
4)
Streptomycin
(N= 7)
Total
(N= 107)
^P
) 1 (14.3%) 19 (17.8%) 0.380
) 0 (0.0%) 4 (3.7%) 1.000
) 0 (0.0%) 1 (0.9%) 1.000
) 0 (0.0%) 2 (1.9%) 0.225
) 0 (0.0%) 1 (0.9%) 0.196
) 1 (14.3%) 3 (2.8%) 0.291
) 0 (0.0%) 1 (0.9%) 1.000
) 0 (0.0%) 6 (5.6%) 0.904
) 1 (14.3%) 11 (10.3%) 0.434
) 0 (0.0%) 4 (3.7%) 1.000
%) 4 (57.1%) 59 (55.1%) 0.108
) 2 (28.6%) 48 (44.9%) <0.001*
%) 2 (28.6%) 25 (23.4%) 0.782
) 5 (71.4%) 23 (21.5%) 0.011*
) 1 (14.3%) 9 (8.4%) 0.193
) 0 (0.0%) 10 (9.3%) 0.104
Table 23 Comparison between DM and non-DM cases as
regards the different side effects among the studied cases.
Side eﬀects DM (N= 32) Non-DM (N= 75) #P
Ototoxicity 9 (28.1%) 10 (13.3%) 0.067
Nephrotoxicity 3 (9.4%) 1 (1.3%) 0.045*
Dizziness 0 (0.0%) 1 (1.3%) 0.512
Hypokalemia 9 (28.1%) 19 (25.3%) 0.764
Hypomagnesaemia 1 (3.1%) 1 (1.3%) 0.531
Hyponatremia 0 (0.0%) 1 (1.3%) 0.512
IBS 6 (18.8%) 18 (24.0%) 0.551
Hepatotoxicity 6 (18.8%) 4 (5.3%) 0.029*
Gynecomastia 1 (3.1%) 2 (2.7%) 0.895
Hypothyroidism 1 (3.1%) 10 (13.3%) 0.111
Arthritis 1 (3.1%) 0 (0.0%) 0.124
GERD 16 (50.0%) 43 (57.3%) 0.485
PN 14 (43.8%) 43 (57.3%) 0.197
Hypoalbuminemia 4 (12.5%) 2 (2.7%) 0.043*
Skin 2 (6.3%) 9 (12.0%) 0.370
Depression 1 (3.1%) 3 (4.0%) 0.827
# Chi square test.
* Signiﬁcant.
Figure 15 Comparison between DM and non-DM cases as
regards the different side effects among the studied cases.
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at least during the intensive phase.
It must be noticed that the total duration of injection is at
least 8 months, as a total duration, or at least 6 months after
sputum conversion and, the total duration of treatment course
is at least 20 months. The duration could be extended to other
three months. The same is applicable for the total duration of
treatment [4].
Timely and aggressive management of adverse effects is
essential. Without it, mortality and permanent morbidity can
be the result, in addition to patient non-adherence. Even if
the adverse effects are not particularly dangerous, prompt
intervention is important. Patients may have signiﬁcant anxi-
ety about an adverse effect if they do not understand why it
is happening. This may in turn augment the severity of the
adverse effect, eg. nausea and vomiting [17].
The current study is a retrospective one to assess side effects
of second-line TB drugs in patients treated for MDR-TB at
Abbassia Chest Hospital from 1st of January 2009 till 1st of
January 2012.This study included 107 patients admitted at MDR ward at
Abbassia Chest Hospital, patients who were readmitted to the
ward were excluded.
All the patients received second line antituberculous drugs:
 Kanamycin (54)
 Amikacin (34)
 Ethionamide (107)
 Capreomycin (14)
 Cycloserine (107)
 PAS (107)
 Oﬂoxacin (107)
 Streptomycin (2)
In this study, the mean of age was 37.1 years, representing
the period of physical, mental and occupational stress. This
result did not coincide with that of Madkour et al. [18], who
stated that in Sayeda Zeinab district, TB was mainly a disease
of adults between 20 and 29 years of age. This difference might
be due to that Madkour et al’s. study was done in a localized
area (Sayeda Zeinab) that gave small representative data and
also their study was not a recent one and so not all cases of
TB had been discovered and had been registered. On the other
hand the result matched with those of Sagwa et al. [19], who
reported that the mean age group was 34.7 years and those
of To¨ru¨n et al. [20], who stated that the mean age group was
37.8 years. Also, this result coincided with Isaakidis et al.
[21], who showed that the mean age group was 35.5 years,
and supported by Modongo and Zetola [22], who stated that
the mean age was 37 years.
In this study, males were 78 cases (72.9%) and females were
29 cases (27.1%). This coincides with the epidemiological pic-
ture of tuberculosis where males are more exposed to infection
in the community than females because of occupational and
mental stress or other social factors which prevent females
from seeking medical advice, which may cause a false lowering
of the incidence rate in females. This result coincided with
Chung-Delgado et al. [23], who reported that the percentage
of MDR-TB males was 76% and that of females was 24%.
This result is also in agreement with To¨ru¨n et al. [20], who
reported that 79% of MDR-TB patients in their study were
males and 21% were females. Also, it matched with Sagwa
et al. [19], who reported that 66% of MDR-TB patients in
their study were males and 34% were females.
It was noticed that the most frequent special habit among
the studied cases was tobacco smoking [29 cases (27.1%)], fol-
lowed by drug addiction [6 cases (5.6%)] and the third was
alcohol intake [4 cases (3.7%)]. This result did not coincide
with that of Fawzy et al. [24], who reported that there was
no statistical relation as regards smoking among TB patients.
Fawzy et al. study included only 21 MDR patients admitted
at Abbassia Chest Hospital as well as in Chest Clinics in
Cairo. This difference might be due to that the data of the
patients in chest clinics might not be so accurate specially as
regarding special habits of the patients. Also, this result did
not coincide with that of Kamal et al. [25], who revealed that
in MDR TB, smokers were 61.53% and non smokers were
38.47%. There was no signiﬁcant difference detected between
smokers and non smokers MDR TB patients. This difference
may be explained by a relatively small number of patients
upon which this study was done {only 26 MDR TB patients}
and it covered a short period of time (from January 2005 to
Adverse reactions among MDR-TB patients 949December 2005). Oppositely, this result coincided with Safwat
et al. [26], who reported that 35% of the patients were smokers
and 11.1% were addict.
In this study, the most common co-morbidity associated
with MDR TB was diabetes {32 cases (29.9%)}, followed by
chronic chest diseases as chronic obstructive lung disease {12
cases (11.2%)}. This result agreed with those of To¨ru¨n et al.
[20], who reported that the highest co-morbidity among
MDR-TB patients was DM 17.8% of the patients then
COPD (2.2%). Also, it matched with those of Safwat et al.
[26], who reported that the highest co-morbidity among
MDR-TB patients was DM (18.3%) of the patients then
COPD (8.9%). On the other hand, this result did not coincide
with those of Fouad et al. [27], who reported that there was no
correlation between diabetes mellitus and drug resistance. This
difference might be due to controllability of the disease, state
of immunity and age of the patients.
In this study, acquired resistance was 95.3% and primary
resistance was 4.7%. This might be due to lack of patients’
adherence to chemotherapy or inappropriate regimen of treat-
ment. This result was supported with those of Abd El Hamid
et al. [28], who found that the acquired MDR-TB cases
exceeded the primary MDR-TB cases. The acquired resistance
was 72%, while the primary resistance was 38%. Also; this
result coincided with those of Tag El Din et al. [29], who found
that the acquired MDR-TB cases exceeded the primary MDR-
TB cases. The acquired resistance was 72% while the primary
resistance was 28%.
In the present study, cured patients were 99 cases (92.5%),
dead patients were 7 cases (6.5%) and defaulters were 1 case
(0.9%). This result did not match with those of Mota et al.
[30], who reported that 67% died, 13% had a favorable out-
come, and 9% were defaulters. Also, the result did not match
with those of Isaakidis et al. [21], who reported that 19.4%
were successfully treated, 20.9% died, defaulted 13.4%. This
difference might be due to that Isaakidis et al., study enrolled
67 patients only. On the other hand, the result coincided with
Shin et al. [31], who studied the outcome of treatment of MDR
TB patients with standardized regimens and reported that
76.0% were cured, 4.9% died and 11.5% defaulted. Again,
the result matched with those of Anderson et al. [32], who
reported that 70.6% were cured, 6.9% died.
The 94.4% prevalence of adverse events observed in the
current study is higher than that reported in other studies,
Bloss et al. [33] and Nathanson et al. [15], where it ranged from
69% to 86%. It was slightly lower than the 96% reported by
Tupasi et al. [34] in their study of 117 patients in the
Philippines. The reasons for the heterogeneity in the preva-
lence of adverse events across the various studies are unclear,
but might be related to several possible factors such as: differ-
ences in deﬁnitions of adverse event terminologies across set-
tings, whether the adverse event was symptomatic and
patient-reported (subjective) or clinician-validated (objective),
whether all or only the severe and serious adverse events were
studied, variations in the use of speciﬁc anti-TB agents, and/or
the differences in co-morbidities and other covariates between
study settings.
In the present study, the frequency of side effects of pre-
scribed drugs was as follows; GERD 57%, peripheral neuritis
53.3%, hypokalemia 26.2%, irritable bowel syndrome 22.4%,
ototoxicity 17.8%, skin reaction 10.3%, hypothyroidism
10.3%, hepatotoxicity 9.3%, hypoalbuminemia 5.6%,depression 3.7%, arthritis 0.9%, gynecomastia 2.8%, hypona-
tremia 5.6%, hypomagnesaemia 1.9%, dizziness 0.9% and
nephrotoxicity 3.7%. This result coincides with those of
El-Naggar et al. [35], who stated that the most frequent side
effects of Anti TB drugs were gastrointestinal manifestations
(84%) and peripheral neuritis (58.4%). Also, this result agreed
with those of Safwat et al. [26], who reported that adverse
effects were as follows: 88.8% Gastrointestinal, peripheral
neuritis 76.7% and hypokalemia 23.3%. Oppositely, the result
did not coincide with those of To¨ru¨n et al. [20], who reported
that the highest adverse effects were ototoxicity 41.8%,
Psychological 21.3% and Gastrointestinal 14%. This differ-
ence might be due to the fact that To¨ru¨n study included 263
MDR TB patients who received individualized treatment for
MDR-TB between April 1992 and June 2004 at Istanbul,
Turkey and also the author said that the frequent and early
occurrence of ototoxicity may be due to the extended exposure
to amino glycosides and Capreomycin during or prior to
MDR-TB treatment. Again, the result did not match with that
of Jacobs and Ross [36], who reported that the highest adverse
effects were ototoxicity (28.7%); peripheral neuropathy
(23.2%); diarrhea, nausea and vomiting (20.5%). This differ-
ence might be due to the fact that Jacobs’ study enrolled 350
MDR TB patients from South African Chest Clinic, the
majority of chest clinic’s patients were retreatment cases.
Among 107 patients who were screened for electrolyte
abnormalities, 26.2% had hypokalemia, deﬁned as a potas-
sium level of <3.5 mEq/L. Diagnosis of low serum potassium
occurred, on average, after 3 months of individualized therapy.
Multivariate analysis of risk factors for this adverse reaction
identiﬁed two causes: administration of Capreomycin, and
low initial body weight. Comparison between cases with and
without hypokalemia as regards prescribed anti-tuberculous
showed that there was no signiﬁcant difference between them
and this may be because the patients received other drugs
rather than aminoglycosides that can cause hypokalemia.
This result partially coincides with that of Shin et al. [37],
who reported that 31% of the cases developed hypokalemia
and said that it might be due two causes: administration of
Capreomycin, and low initial body weight.
In our study, nephrotoxicity frequency was 3.7%, due to
amino glycosides, but was not as high as ototoxicity
(17.8%), and this was similar to the results of Furin et al.
[38], Jager and Altena [39]. Three cases were major (need stop-
page or withdrawal of the drug) and one case was minor (no
stoppage or withdrawal of the drug but just follow up) and
that coincided with To¨ru¨n et al. [20], who reported 2 cases with
nephrotoxicity and they were major.
In the current study, 19 cases developed ototoxicity
(17.8%), 2 of them were minor, and 17 were major, and that
was similar to the results of To¨ru¨n et al. [20], who reported that
the majority of cases who developed ototoxicity needed stop-
page or withdrawal of the drug (major side effects).
In our study, hepatotoxicity was not rare {(10 cases) 9.3%}.
Once this side effect had occurred, all drugs were suspended
until liver function tests return to baseline. Gradually intro-
ducing the drugs by giving them in increasing number and
dosage is recommended. Those drugs most commonly associ-
ated with hepatotoxicity should be added last. All the cases
had hepatotoxicity as a major side effect and that did not coin-
cide with the results of To¨ru¨n et al. [20], who reported 8 cases
as a major and 4 cases as a minor. This difference might be
950 M.A. Tag El Din et al.attributed to the difference in the number of enrolled cases in
each study, drugs prescribed or the duration of treatment and
follow up.
Psychiatric disorders were also observed in 4 patients
(3.7%) under treatment who suffered from depression and this
was partly attributable to a loss of conﬁdence in the health ser-
vices due to previous treatment failures. Patients’ trust in the
treatment they are receiving is crucial if they are to continue
with such a long treatment regimen. Treatment managers need
to be aware of this and ensure that staff administering treat-
ment regimens do all they can to win the trust and build the
conﬁdence of the patients in their care. Some drugs used in
MDR-TB treatment also cause psychiatric disorders.
Psychosis has been reported as a side effect of CS and ﬂuoro-
quinolones, and depression, while it has been associated with
other drugs in the MDR-TB treatment regimen, is primarily
associated with CS [40]. In response to psychosis and depres-
sion, we initiated antidepressant or anti-psychotic therapy as
and when needed.
In the current study and according to the severity code,
GIT side effects were 26.2% mild and 73.7% moderate and
that did not coincide with the results of Isaakidis et al. [21],
who reported that 24% of GIT symptoms were mild and
12% were moderate. This difference might be due to the fact
that Isaakidis et al. enrolled 67 patients only in their study.
In our study and according to the severity code, 19.3% of
the peripheral neuritis cases were mild and 80.7% were moder-
ate and this partially matched with the results of Isaakidis et al.
[21], who reported that 4% of PN symptoms were mild and
21% were moderate.
Hypothyroidism developed in only 10.3% of studied
patients and that coincided with Furin et al. [38], who reported
a 10% level of hypothyroidism in their series.
Most adverse reactions occurred during the ﬁrst 3 months
of treatment. Every effort was made to avoid permanent dis-
continuation of any anti-tuberculosis drug unless the adverse
reaction was life threatening or could not be controlled other-
wise. These results match partially with those of To¨ru¨n et al.
[20], who reported that the adverse effects began 4 months
after beginning of treatment. In addition, this result was sup-
ported with those of Isaakidis et al. [21], who reported that
the adverse effects occurred between 2nd, and 4th month of
MDR-TB treatment initiation and those of Van der Walt
et al. [41], who reported that the adverse effects occurred dur-
ing the ﬁrst 4 months of MDR-TB treatment. On the other
hand, this result did not agree with those of Shin et al. [31],
who reported that most adverse reactions occurred during
the ﬁrst 8 months of treatment. This difference might be due
to the fact that in Shin study, there were 244 MDR TB patients
enrolled from Russia and the duration of the study was only
two years between 10 September 2000 and 10 September 2002.
In our study, comparison between cases with and without
ototoxicity as regards the prescribed anti-tuberculous drugs
showed that there was no signiﬁcant relation between
Kanamycin and ototoxicity and this result coincided with that
of Duggal and Sarkar [42].
In our study, comparison between cases with and without
peripheral neuritis as regards the prescribed anti-tuberculous
drugs showed that there was no signiﬁcant relation between
it and any prescribed antibiotic. This result agreed with that
of Shin et al. [16], who reported that although there was a ten-
dency for patients with peripheral neuropathy to be older,male and have co-morbid conditions, these variables were
not statistically signiﬁcant.
In our study, side effects occurred more in non diabetics
(70%) compared to diabetic patients (29.9%) and this might
be due to the fact that the number of diabetic patients included
was low (32). This result coincided with that of Chung-
Delgado et al. [23], who reported that 92.7% of patients were
non diabetics and 7.4% were diabetic.Limitation of the study
By using retrospective data, we encountered instances of miss-
ing patient treatment records and missing data on speciﬁc vari-
ables. Furthermore, it was not possible to perform qualitative
causality assessment of the adverse events using the available
data, especially given the paucity of laboratory data. The
adverse events recorded on the patients’ side effect monitoring
form were based on patient-reported symptoms. Hence, there
was a possibility of subjectivity and of selective under-report-
ing of adverse events by patients or the selective recording of
adverse events by clinicians, which may have biased the results
away from the true prevalence. Some symptoms of reported
adverse events may have overlapped with symptoms of the
co-morbidities.Conclusions
 There is a relation between both tobacco smoking and drug
addiction, and MDR TB.
 The most common type of resistance is acquired resistance
because of lack of adherence to treatment or inappropriate
treatment.
 No statistical difference between males and females accord-
ing to associated diseases or drug sensitivity test.
 The most common co-morbidities associated with MDR
TB are diabetes and chronic obstructive lung diseases.
 The most important predictors of patients’ outcome are
sputum conversion, number of previous TB treatment and
presence of co-morbidities.Recommendations
 Regular drug resistance survey is important to monitor the
cases.
 The best way to prevent MDR is: early detection and
prompt treatment of TB.
 In the light of increasing incidence of resistance of tubercu-
losis, it is recommended that drug susceptibility testing
should be done for all patients if feasible.
 The application of the Directly Observed Therapy with
short course chemotherapy should be very strict to elimi-
nate the problem of non adherence to therapy.
 To limit the resistance to Streptomycin and Rifampicin,
they should not be prescribed for diseases other than
tuberculosis.
 Restricted availability of Rifampicin and Streptomycin in
private pharmacies except by prescription.
 There is an urgent need to develop new anti-tuberculous
drugs to shorten the duration of treatment and to make
development of resistance less likely to emerge.
Adverse reactions among MDR-TB patients 951 Health education about TB and hazards of tobacco smok-
ing and drug addiction.
 In TB patients with associated diseases, these associated dis-
eases should be well controlled, especially diabetes.
 Adherence of patients to treatment even at home is more
important than admission at hospital because resistance is
more liable to occur at hospital.
 Regular follow up of treatment to detect early side effects of
medications.
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